Clusterin and chemoresistance

Advances in Cancer Research

Volumn 105, Issue , 2009, Pages 77-92

  Djeu, Julie Y ^a   Wei, Sheng ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLU PROTEIN, HUMAN; CLUSTERIN;

DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; REVIEW;

CLUSTERIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; OXIDATIVE STRESS;

EID: 73949102933     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(09)05005-2     Document Type: Review

References (79)

1. Ammar, H., and Closset, J. L. (2008). Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 283, 12851-12861.
2. Bettuzzi, S., Hiipakka, R. A., Gilna, P., and Liao, S. T. (1989). Identification of an androgenrepressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem. J. 257, 293-296.
3. Biroccio, A., et al. (2005). Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. J. Cell. Physiol. 204, 463-469.
4. Borst, P., et al. (2007). What makes tumors multidrug resistant? Cell Cycle 6, 2782-2787.
5. Buttyan, R., et al. (1989). Induction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell. Biol. 9, 3473-3481.
6. Cervellera, M., et al. (2000). Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275, 21055-21060.
7. Chi, K. N., et al. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97, 1287-1296.
8. Chi, K. N., et al. (2008). Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 180, 565-570, discussion 570.
9. Chia, S., et al. (2009). Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin. Cancer Res. 15, 708-713.
10. Cochrane, D. R., et al. (2007). Differential regulation of clusterin and its isoforms by androgens in prostate cells. J. Biol. Chem. 282, 2278-2287.
11. Criswell, T., et al. (2003). Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol. Ther. 2, 372-380.
12. Criswell, T., et al. (2005). Delayed activation of insulin-like growth factor-1 receptor/Src/ MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem. 280, 14212-14221.
13. Danik, M., et al. (1991). Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl. Acad. Sci. USA 88, 8577-8581.
14. Dumont, P., et al. (2002). Overexpression of apolipoprotein J in human fibroblasts protects against cytotoxicity and premature senescence induced by ethanol and tert-butylhydroperoxide. Cell Stress Chaperones 7, 23-35.
15. Galletti, E., et al. (2007). Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes. ChemMedChem 2, 920-942.
16. Gleave, M. E., et al. (2001). Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58, 39-49.
17. Haldar, S., et al. (1997). Bcl2 is the guardian of microtubule integrity. Cancer Res. 57, 229-233.
18. Hoeller, C., et al. (2005). Clusterin regulates drug-resistance in melanoma cells. J. Invest. Dermatol. 124, 1300-1307.
19. Hough, C. D., et al. (2001). Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61, 3869-3876.
20. Jin, G., and Howe, P. H. (1997). Regulation of clusterin gene expression by transforming growth factor beta. J. Biol. Chem. 272, 26620-26626.
21. Jin, G., and Howe, P. H. (1999). Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur. J. Biochem. 263, 534-542.
22. July, L. V., et al. (2002). Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50, 179-188.
23. July, L. V., et al. (2004). Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3, 223-232.
24. Kelly, W. K., and Marks, P. A. (2005). Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2, 150-157.
25. Lee, C. H., et al. (2002). Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells. Urology 60, 516-520.
26. Leger, J. G., et al. (1987). Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem. Biophys. Res. Commun. 147, 196-203.
27. Liu, T., et al. (2009). Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur. J. Cancer 45, 1846-1854.
28. Loblaw, D. A., et al. (2007). Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25, 1596-1605.
29. Loison, F., et al. (2006). Up-regulation of the clusterin gene after proteotoxic stress: Implication of HSF1-HSF2 heterocomplexes. Biochem. J. 395, 223-231.
30. Lourda, M., et al. (2007). Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int. J. Cancer 120, 611-622.
31. Martin, L. P., et al. (2008). Platinum resistance: The role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295.
32. McDonnell, T. J., et al. (1992). Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944.
33. Miyake, H., et al. (2000a). Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655-1663.
34. Miyake, H., et al. (2000b). Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60, 2547-2554.
35. Miyake, H., et al. (2000c). Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 60, 170-176.
36. Miyake, H., et al. (2001a). Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7, 4245-4252.
37. Miyake, H., et al. (2001b). Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol. Urol. 5, 105-111.
38. Miyake, H., et al. (2004a). Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J. Urol. 171, 2477-2481.
39. Miyake, H., et al. (2004b). Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61, 318-323.
40. Miyake, H., et al. (2006). Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 68, 609-614.
41. Mourra, N., et al. (2007). Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours. Histopathology 50, 331-337.
42. Nahta, R., et al. (2006). Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269-280.
43. Papenfuss, K., et al. (2008). Death receptors as targets for anti-cancer therapy. J. Cell. Mol. Med. 12, 2566-2585.
44. Parczyk, K., et al. (1994). Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J. Cancer Res. Clin. Oncol. 120, 186-188.
45. Patterson, S. G., et al. (2006). Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25, 6113-6122.
46. Petrylak, D. P., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520.
47. Pucci, S., et al. (2004). Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23, 2298-2304.
48. Pucci, S., et al. (2009). Interleukin-6 affects cell death escaping mechanisms acting on Bax- Ku70-Clusterin interactions in human colon cancer progression. Cell Cycle 8, 473-481.
49. Rabik, C. A., and Dolan, M. E. (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9-23.
50. Ranney, M. K., et al. (2007). Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. Biochim. Biophys. Acta 1772, 1103-1111.
51. Redondo, M., et al. (2000). Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157, 393-399.
52. Sallman, D. A., et al. (2007). Clusterin mediates TRAIL resistance in prostate tumor cells. Mol. Cancer Ther. 6, 2938-2947.
53. Santilli, G., et al. (2003). Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J. Biol. Chem. 278, 38214-38219.
54. Sawada, M., et al. (2003). Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5, 320-329.
55. Scatena, C. D., et al. (1998). Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 273, 30777-30784.
56. Schepeler, T., et al. (2007). Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. J. Mol. Signal. 2, 6.
57. Sensibar, J. A., et al. (1995). Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 55, 2431-2437.
58. Sintich, S. M., et al. (1999). Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 39, 87-93.
59. So, A., et al. (2005). Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol. Cancer Ther. 4, 1837-1849.
60. Song, H., et al. (2009). Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28, 3307-3319.
61. Steinberg, J., et al. (1997). Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3, 1707-1711.
62. Suh, E., et al. (2001). Clusterin gene transcription is activated by caudal-related homeobox genes in intestinal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G149-G156.
63. Takase, O., et al. (2008). Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int. 73, 567-577.
64. Tammela, T. (2004). Endocrine treatment of prostate cancer. J. Steroid Biochem. Mol. Biol. 92, 287-295.
65. Tannock, I. F., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512.
66. Taplin, M. E. (2007). Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 4, 236-244.
67. Thomas-Tikhonenko, A., et al. (2004). Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 64, 3126-3136.
68. Trougakos, I. P., et al. (2004). Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64, 1834-1842.
69. Trougakos, I. P., et al. (2009a). Advances and challenges in basic and translational research on clusterin. Cancer Res. 69, 403-406.
70. Trougakos, I. P., et al. (2009b). Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 15, 48-59.
71. Wang, J., et al. (1998). A model for Ku heterodimer assembly and interaction with DNA. Implications for the function of Ku antigen. J. Biol. Chem. 273, 31068-31074.
72. Watari, H., et al. (2008). Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol. Oncol. 108, 527-532.
73. Wei, L., et al. (2009). Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int. J. Cancer 125, 791-806.
74. Wellmann, A., et al. (2000). Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96, 398-404.
75. Xie, D., et al. (2005). Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103, 277-283.
76. Yang, C. R., et al. (2000). Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912.
77. Zellweger, T., et al. (2001). Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360-367.
78. Zellweger, T., et al. (2002). Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8, 3276-3284.
79. Zhang, H., et al. (2005). Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 7, 909-915.